Advances in non-invasive drug delivery for atherosclerotic heart disease

Abstract

Taken together, these studies show that non-invasive drug-delivery systems may become promising tools to rescue CHD patients from the risks of severe and life-threatening lesions that should be more energetically treated.

Tissue Uptake Mechanisms Involved in the Clearance of Non‐Protein Nanoparticles that Mimic LDL Composition: A Study with Knockout and Transgenic Mice

“…LDE, constituted of nanoparticles with an average 40-60 nm, is not likely to cross the brain-blood barrier. The pioneer observation that LDE can target neoplastic and inflammatory, atherosclerotic tissues, leading to marked reduction of the toxicity of chemotherapeutic agents and an increase in their pharmacological action, was reiterated in several experimental and clinical studies [18,19]. The results of this study support LDLR and apoE as key players for LDE clearance but suggest that other receptor mechanisms may also have a role in the tissue uptake of this nanoparticle system.…”

“…The pioneer observation that LDE can target neoplastic and inflammatory, atherosclerotic tissues, leading to marked reduction of the toxicity of chemotherapeutic agents and an increase in their pharmacological action, was reiterated in several experimental and clinical studies [18,19]. LDE, constituted of nanoparticles with an average 40-60 nm, is not likely to cross the brain-blood barrier.…”

“…As described above, LDE has great potential as a drug delivery system for the treatment of cancer, atherosclerosis and other chronic inflammatory diseases [18,19]. As described above, LDE has great potential as a drug delivery system for the treatment of cancer, atherosclerosis and other chronic inflammatory diseases [18,19].…”

“…Non-protein, LDL-like nanoparticles with defined lipid composition such as LDE are easy to prepare and label by radioactive and other means and can be used as a tool to explore the plasma lipoprotein metabolism. As described above, LDE has great potential as a drug delivery system for the treatment of cancer, atherosclerosis and other chronic inflammatory diseases [18,19]. Although LDE has a wide distribution in the organs and tissues, the concentration in tumoral tissues, compared to the corresponding normal tissues is remarkable.…”

Triphenylphosphonium and D-α-tocopheryl polyethylene glycol 1000 succinate-modified, tanshinone IIA-loaded lipid-polymeric nanocarriers for the targeted therapy of myocardial infarction

“…NPs-based drug delivery systems have attracted much attention in the treatment of MI and ischemic heart disease. 17,18 NPs comprising inorganic particles, lipid NPs, or polymeric micelles can be targeted toward mitochondria using mitochondriotropic moieties such as TPP and TPMP. 8 Among them, lipid-polymeric nanocarriers (LPNs) have emerged as a multifunctional drug delivery platform, which combines mechanical advantages of polymeric core and biomimetic advantages of phospholipid shell into a single platform.…”